Key result
VEGF pathway inhibitors linked to a ~22-fold higher risk of aortic dissection in cancer patients.
Why the study?
Although vascular endothelial growth factor pathway inhibitors have been suspected in the onset of aortic dissection, no comparative study has assessed this association.
Do systemic vascular endothelial growth factor pathway inhibitors increase the risk of aortic dissection in patients with malignant neoplasms?
Population
91,055 subjects with underlying malignant neoplasms in Japan
Comparison
Systemic VPIs vs antimalignant neoplasm agents without VPIs
Design
Observational study using Japanese Adverse Drug Event Report database
Follow-up
Median time to onset 105 days (range 4-1363 days)
Authors
Loading...
VPI-induced hypertension may heighten aortic dissection risk in cancer patients; leaves open prospective incidence and monitoring studies.
Observational (n=91,055)
Do systemic vascular endothelial growth factor pathway inhibitors increase the risk of aortic dissection in patients with malignant neoplasms?
Odds Ratio: 22.3 (95% CI 11.2–49.4)
Absolute Event Rate: 0.3% vs 0.01%
Systemic exposure to vascular endothelial growth factor pathway inhibitors is associated with a significantly increased risk of aortic dissection in patients with malignant neoplasms.
Oshima et al. (2017) conducted an observational in Malignant neoplasms (n=91,055). Vascular endothelial growth factor pathway inhibitors (VPIs) vs. Subjects with underlying malignant neoplasms not treated with VPIs was evaluated on Aortic dissection (OR 22.3, 95% CI 11.2-49.4). Systemic exposure to vascular endothelial growth factor pathway inhibitors in patients with cancer was associated with a significantly increased risk of aortic dissection (OR 22.3; 95% CI 11.2-49.4).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: